Institution
University of Arizona
Education•Tucson, Arizona, United States•
About: University of Arizona is a education organization based out in Tucson, Arizona, United States. It is known for research contribution in the topics: Population & Galaxy. The organization has 63805 authors who have published 155998 publications receiving 6854915 citations. The organization is also known as: UA & U of A.
Topics: Population, Galaxy, Star formation, Redshift, Planet
Papers published on a yearly basis
Papers
More filters
••
Association of Universities for Research in Astronomy1, Pontifical Catholic University of Chile2, Harvard University3, European Southern Observatory4, University of California, Berkeley5, University of Arizona6, University of Michigan7, University of Washington8, Space Telescope Science Institute9, University of Hawaii at Manoa10, University of Chile11, Carnegie Learning12, Pennsylvania State University13
TL;DR: The High-Z Supernova Search (HSSS) as mentioned in this paper is an international collaboration to discover and monitor Type Ia supernovae (SNe Ia) at z > 0.2 with the aim of measuring cosmic deceleration and global curvature.
Abstract: The High-Z Supernova Search is an international collaboration to discover and monitor Type Ia supernovae (SNe Ia) at z > 0.2 with the aim of measuring cosmic deceleration and global curvature. Our collaboration has pursued a basic understanding of supernovae in the nearby universe, discovering and observing a large sample of objects and developing methods to measure accurate distances with SNe Ia. This paper describes the extension of this program to z ≥ 0.2, outlining our search techniques and follow-up program. We have devised high-throughput filters that provide accurate two-color rest frame B and V light curves of SNe Ia, enabling us to produce precise, extinction-corrected luminosity distances in the range 0.25 M=-0.2 -->−0.8+1.0 if ΩΛ = 0. For a spatially flat universe composed of normal matter and a cosmological constant, we find Ω -->M=0.4 -->−0.4+0.5, Ω${Λ}$ -->=0.6 -->−0.5+0.4. We demonstrate that with a sample of ~30 objects, we should be able to determine relative luminosity distances over the range 0 < z < 0.5 with sufficient precision to measure ΩM with an uncertainty of ±0.2.
1,280 citations
••
TL;DR: It is suggested that the use of some or all of these homologous phenoxazone ethers will provide both a simple routine test for the characterization of several types of inducing agents and a powerful tool for investigating the biochemical basis for cyt.
1,280 citations
••
Harvard University1, York Hospital2, Mayo Clinic3, National Institutes of Health4, Fox Chase Cancer Center5, University of Texas MD Anderson Cancer Center6, LDS Hospital7, Saint Barnabas Medical Center8, University of Arizona9, University of Southern California10, University of California, San Francisco11
TL;DR: The current state of knowledge regarding pathologic prognostic factors and predictive factors in colorectal carcinoma was evaluated and recommendations were made to increase the uniformity and completeness of pathologic evaluation of tumor specimens and to improve patient care.
Abstract: Background Under the auspices of the College of American Pathologists, the current state of knowledge regarding pathologic prognostic factors (factors linked to outcome) and predictive factors (factors predicting response to therapy) in colorectal carcinoma was evaluated. A multidisciplinary group of clinical (including the disciplines of medical oncology, surgical oncology, and radiation oncology), pathologic, and statistical experts in colorectal cancer reviewed all relevant medical literature and stratified the reported prognostic factors into categories that reflected the strength of the published evidence demonstrating their prognostic value. Accordingly, the following categories of prognostic factors were defined. Category I includes factors definitively proven to be of prognostic import based on evidence from multiple statistically robust published trials and generally used in patient management. Category IIA includes factors extensively studied biologically and/or clinically and repeatedly shown to have prognostic value for outcome and/or predictive value for therapy that is of sufficient import to be included in the pathology report but that remains to be validated in statistically robust studies. Category IIB includes factors shown to be promising in multiple studies but lacking sufficient data for inclusion in category I or IIA. Category III includes factors not yet sufficiently studied to determine their prognostic value. Category IV includes factors well studied and shown to have no prognostic significance. Materials and methods The medical literature was critically reviewed, and the analysis revealed specific points of variability in approach that prevented direct comparisons among published studies and compromised the quality of the collective data. Categories of variability recognized included the following: (1) methods of analysis, (2) interpretation of findings, (3) reporting of data, and (4) statistical evaluation. Additional points of variability within these categories were defined from the collective experience of the group. Reasons for the assignment of an individual prognostic factor to category I, II, III, or IV (categories defined by the level of scientific validation) were outlined with reference to the specific types of variability associated with the supportive data. For each factor and category of variability related to that factor, detailed recommendations for improvement were made. The recommendations were based on the following aims: (1) to increase the uniformity and completeness of pathologic evaluation of tumor specimens, (2) to enhance the quality of the data needed for definitive evaluation of the prognostic value of individual prognostic factors, and (3) ultimately, to improve patient care. Results and conclusions Factors that were determined to merit inclusion in category I were as follows: the local extent of tumor assessed pathologically (the pT category of the TNM staging system of the American Joint Committee on Cancer and the Union Internationale Contre le Cancer [AJCC/UICC]); regional lymph node metastasis (the pN category of the TNM staging system); blood or lymphatic vessel invasion; residual tumor following surgery with curative intent (the R classification of the AJCC/UICC staging system), especially as it relates to positive surgical margins; and preoperative elevation of carcinoembryonic antigen elevation (a factor established by laboratory medicine methods rather than anatomic pathology). Factors in category IIA included the following: tumor grade, radial margin status (for resection specimens with nonperitonealized surfaces), and residual tumor in the resection specimen following neoadjuvant therapy (the ypTNM category of the TNM staging system of the AJCC/UICC). (ABSTRACT TRUNCATED)
1,279 citations
••
TL;DR: Results indicate BAK1 is a component of BR signaling, and Expression of a dominant-negative mutant allele of B AK1 causes a severe dwarf phenotype, resembling the phenotype of null bri1 alleles.
1,275 citations
••
TL;DR: Together, stress granules and P-bodies reveal a dynamic cycle of distinct biochemical and compartmentalized mRNPs in the cytosol, with implications for the control of mRNA function.
1,271 citations
Authors
Showing all 64388 results
Name | H-index | Papers | Citations |
---|---|---|---|
Simon D. M. White | 189 | 795 | 231645 |
Julie E. Buring | 186 | 950 | 132967 |
David H. Weinberg | 183 | 700 | 171424 |
Richard Peto | 183 | 683 | 231434 |
Xiaohui Fan | 183 | 878 | 168522 |
Dennis S. Charney | 179 | 802 | 122408 |
Daniel J. Eisenstein | 179 | 672 | 151720 |
David Haussler | 172 | 488 | 224960 |
Carlos S. Frenk | 165 | 799 | 140345 |
Jian-Kang Zhu | 161 | 550 | 105551 |
Tobin J. Marks | 159 | 1621 | 111604 |
Todd Adams | 154 | 1866 | 143110 |
Jane A. Cauley | 151 | 914 | 99933 |
Wei Zheng | 151 | 1929 | 120209 |
Daniel L. Schacter | 149 | 592 | 90148 |